Merck, Inc.
🇵🇭Philippines
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15000
- Registration Number
- NCT00060476
Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease
Phase 2
Completed
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00056147
Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)
Phase 3
Terminated
- Conditions
- First Posted Date
- 2002-12-05
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 702
- Registration Number
- NCT00050336
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-11-15
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00049842
Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-11-08
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 631
- Registration Number
- NCT00048724
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 600
- Registration Number
- NCT00048607
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-11-05
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 800
- Registration Number
- NCT00048594
Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-09-04
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 602
- Registration Number
- NCT00044486
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-07-23
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 324
- Registration Number
- NCT00042029
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)
Phase 1
Terminated
- Conditions
- First Posted Date
- 2002-07-01
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00040534
© Copyright 2024. All Rights Reserved by MedPath